EGR1 and cancer: ANGPTL1 overexpression inhibits the MET receptor-AKT/ERK-Egr-1-Slug signaling cascade, repressing the epithelial–mesenchymal transition and thereby counteracting sorafenib resistance and cancer stemness in HCC cells (53).